Literature DB >> 25883497

Commentary.

Lukas A Holzer1.   

Abstract

Entities:  

Year:  2015        PMID: 25883497      PMCID: PMC4387828     

Source DB:  PubMed          Journal:  J Neurosci Rural Pract        ISSN: 0976-3155


× No keyword cloud information.
Alkaptonuria is a rare autosomal recessive disorder of tyrosine degradation that is associated with a deficient homogentisate 1,2-dioxygenase activity in the liver. In patients with alkaptonuria, the gene for homogentisate 1,2-dioxygenase is mutated. Homogentisate 1,2-dioxygenase deficiency leads to excretion of large quantities of homogentisic acid in the urine. In urine and in collagen-rich connective tissues, homogentisic acid oxidizes to benzoquinones, which in turn form melanin-like polymers that cause its dark color changes. Accumulation of homogentisic acid and its metabolites causes ochronosis in collagen-rich connective tissues with darkening of cartilage and bone. These changes lead to arthritis, joint destruction and deterioration of the spine and large joints. Furthermore, cardiac valvular disease and renal and prostate stones occur, however generally at a later stage of disease.[12] Ochronotic arthropathy is common in alkaptonuria. Various cases of ochronotic arthropathy have been described in different anatomical regions. In most of these cases surgical reconstruction with arthroplasty has been performed.[34] A novel therapy for alkaptonuria could be Nitisinone, which is a potent inhibitor of the second enzyme in the tyrosine catabolic pathway.[5] In a prospective, randomized clinical trial in 40 patients over a 3-year period the use of Nitisinone could demonstrate a 95% reduction of homogentisic acid in urine and plasma. Clinically, the primary outcome parameter was hip total range of motion and measures of musculoskeletal function serving as secondary parameters. In both, however, no statistically significant benefit of Nitisinone could be shown.[6] In this issue, Rana et al. report about a patient with alkaptonuria and ochronotic arthropathy of the shoulders that was treated with bilateral total shoulder joint arthroplasty.[7] Furthermore, they report about psychological distress due to alkaptonuria in their patient. Psychological distress hasn’t been recognized often and gained attention in alkaptonuria patients yet. Generally, psychological issues are associated with various musculoskeletal conditions.[8] So, this seems to be an interesting and important point that needs further attention and should be addressed in future studies.
  8 in total

1.  A 3-year randomized therapeutic trial of nitisinone in alkaptonuria.

Authors:  Wendy J Introne; Monique B Perry; James Troendle; Ekaterini Tsilou; Michael A Kayser; Pim Suwannarat; Kevin E O'Brien; Joy Bryant; Vandana Sachdev; James C Reynolds; Elizabeth Moylan; Isa Bernardini; William A Gahl
Journal:  Mol Genet Metab       Date:  2011-05-06       Impact factor: 4.797

2.  Ochronosis of the hip joint.

Authors:  Lukas A Holzer; Andreas Leithner; Gerald Gruber
Journal:  J Rheumatol       Date:  2013-04       Impact factor: 4.666

Review 3.  New developments in ochronosis: review of the literature.

Authors:  Julie M Keller; William Macaulay; Ohannes A Nercessian; Israeli A Jaffe
Journal:  Rheumatol Int       Date:  2004-08-21       Impact factor: 2.631

4.  Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone.

Authors:  Andrew J Preston; Craig M Keenan; Hazel Sutherland; Peter J Wilson; Brenda Wlodarski; Adam M Taylor; Dominic P Williams; Lakshminarayan R Ranganath; James A Gallagher; Jonathan C Jarvis
Journal:  Ann Rheum Dis       Date:  2013-03-19       Impact factor: 19.103

5.  Devastating ochronotic arthropathy with successful bilateral hip and knee arthroplasties.

Authors:  Kentaro Araki; Akihiro Sudo; Masahiro Hasegawa; Atsumasa Uchida
Journal:  J Clin Rheumatol       Date:  2009-04       Impact factor: 3.517

6.  Natural history of alkaptonuria.

Authors:  Chanika Phornphutkul; Wendy J Introne; Monique B Perry; Isa Bernardini; Mark D Murphey; Diana L Fitzpatrick; Paul D Anderson; Marjan Huizing; Yair Anikster; Lynn H Gerber; William A Gahl
Journal:  N Engl J Med       Date:  2002-12-26       Impact factor: 91.245

7.  Alkaptonuria, more than just a mere disease.

Authors:  Abdul Qayyum Rana; Usman Saeed; Ismael Abdullah
Journal:  J Neurosci Rural Pract       Date:  2015 Apr-Jun

8.  Body image and self-esteem in lower-limb amputees.

Authors:  Lukas A Holzer; Florian Sevelda; Georg Fraberger; Olivia Bluder; Wolfgang Kickinger; Gerold Holzer
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.